234 related articles for article (PubMed ID: 8141814)
1. Pharmacological studies on a new Dihydrothienopyridine calcium antagonist. 2nd communication: effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4- (3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate on the 1,4-dihydropyridine binding sites in the brain and on isolated arteries in the Cynomolgus monkey.
Nakajima M; Adachi I; Ueda M
Arzneimittelforschung; 1993 Dec; 43(12):1276-82. PubMed ID: 8141814
[TBL] [Abstract][Full Text] [Related]
2. Effects of the novel water-soluble calcium antagonist (+/-)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride on the responses of isolated canine arteries.
Kanda M; Shirahase H; Kurahashi K; Wada K; Nakamura S; Matsui H; Fukata F
Arzneimittelforschung; 1995 Aug; 45(8):831-5. PubMed ID: 7575741
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 1st communication: comparative studies on the cardiovascular effects of methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2,3- b]pyridine-5-carboxylate and its two enantiomers in experimental animals.
Ueda M; Matsumura S; Masui M; Matsuura E; Uno O; Kawakami M; Ninomiya M; Adachi I
Arzneimittelforschung; 1993 Dec; 43(12):1270-5. PubMed ID: 8141813
[TBL] [Abstract][Full Text] [Related]
4. Effects of the novel water-soluble calcium antagonist (+/-)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride on the endothelium-independent and endothelium-dependent contraction in isolated canine cerebral arteries.
Kanda M; Shirahase H; Wada K; Nakamura S; Matsui H; Fukata F
Arzneimittelforschung; 1996 Jul; 46(7):663-6. PubMed ID: 8842332
[TBL] [Abstract][Full Text] [Related]
5. Cerebrovascular selectivity and vasospasmolytic action of the novel calcium antagonist (+/-)-(E)-1-(3-fluoro-6, 11-dihydrodibenz[b,e]oxepin-11-yl)-4-(3-phenyl-2-propenyl)-piperazine dimaleate in isolated cerebral arteries of the rabbit and dog.
Minato H; Hashizume M; Masuda Y; Fujitani B; Hosoki K
Arzneimittelforschung; 1997 Apr; 47(4):339-46. PubMed ID: 9150852
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs.
Ueda M; Matsumura S; Masui M; Matsuura E; Kawakami M; Fujitomo H; Umeda T; Kagawa H; Hirohata S; Shima K
Arzneimittelforschung; 1993 Dec; 43(12):1282-90. PubMed ID: 8141815
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
8. Prolonged depolarization increases the pharmacological effect of dihydropyridines and their binding affinity for calcium channels of vascular smooth muscle.
Morel N; Godfraind T
J Pharmacol Exp Ther; 1987 Nov; 243(2):711-5. PubMed ID: 2824756
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 4th communication: prophylactic and therapeutic effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3- b]pyridine-5-carboxylate in stroke-prone spontaneously hypertensive rats.
Ueda M; Masui M; Kawakami M; Matsunaga K; Gemba T; Ninomiya M; Nakano A; Torii M; Adachi I; Ito H
Arzneimittelforschung; 1993 Dec; 43(12):1291-303. PubMed ID: 8141816
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular activities of the new potent and long-lasting antihypertensive calcium entry blocker (+-)-3-ethyl,5-methyl,2- ([2-(formylamino)-ethyl]- thiomethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicar box ylate.
Germini M; Passoni A; Casciarri I; Bosetti P; Piazzoni L; Cazzulani P; Gandolfi CA; Tofanetti O; Ceserani R
Arzneimittelforschung; 1992 Jan; 42(1):1-8. PubMed ID: 1586373
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic and radioligand binding studies of 1,4-dihydropyridines in rat cardiac and vascular preparations: stereoselectivity and voltage dependence of antagonist and activator interactions.
Zheng W; Stoltefuss J; Goldmann S; Triggle DJ
Mol Pharmacol; 1992 Mar; 41(3):535-41. PubMed ID: 1372088
[TBL] [Abstract][Full Text] [Related]
12. Voltage-dependent binding of 1,4-dihydropyridine Ca2+ channel antagonists and activators in cultured neonatal rat ventricular myocytes.
Wei XY; Rutledge A; Triggle DJ
Mol Pharmacol; 1989 Apr; 35(4):541-52. PubMed ID: 2539561
[TBL] [Abstract][Full Text] [Related]
13. Effects of the new long-acting dihydropyridine calcium antagonist pranidipine on the endothelium-dependent relaxation in isolated rat aorta in vitro.
Nakayama N; Ikezono K; Ohura M; Yabuuchi Y
Arzneimittelforschung; 1993 Dec; 43(12):1266-70. PubMed ID: 8141812
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of 3H-nitrendipine binding in rat aortic and cerebral cortex membranes by the new dihydropyridine calcium antagonist benidipine hydrochloride.
Ishii A
Arzneimittelforschung; 1989 Dec; 39(12):1546-50. PubMed ID: 2624603
[TBL] [Abstract][Full Text] [Related]
15. Effects of a new dihydropyridine calcium antagonist on vascular smooth muscles, cardiac muscles and [3H]-nitrendipine binding.
Miura A; Ukai Y; Matsuzaki T; Taniguchi N; Hayashi S; Kano S; Kimura Y; Kimura K; Enomoto H
Arzneimittelforschung; 1986 Sep; 36(9):1323-8. PubMed ID: 3790181
[TBL] [Abstract][Full Text] [Related]
16. Effects of a novel calcium antagonist, S-(+)-methyl-4,7-dihydro-3-isobutyl-6- methyl-4-(3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate (S-312-d), on ischemic amino acid release and neuronal injury in stroke-prone spontaneously hypertensive rats.
Gemba T; Ninomiya M; Matsunaga K; Ueda M
J Pharmacol Exp Ther; 1993 Apr; 265(1):463-7. PubMed ID: 8474028
[TBL] [Abstract][Full Text] [Related]
17. In vitro effects of calcium antagonists PN 200-110, nifedipine, and nimodipine on human and canine cerebral arteries.
Müller-Schweinitzer E; Neumann P
J Cereb Blood Flow Metab; 1983 Sep; 3(3):354-61. PubMed ID: 6223932
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective inhibition of thromboxane-induced coronary vasoconstriction by 1,4-dihydropyridine calcium channel antagonists.
Eltze M; Boer R; Sanders KH; Boss H; Ulrich WR; Flockerzi D
Chirality; 1990; 2(4):233-40. PubMed ID: 1964575
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide (EDRF) enhances the vasorelaxing effect of dihydropyridine calcium antagonists in isolated human middle cerebral arteries.
Akopov SE
Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):101-4. PubMed ID: 8740241
[TBL] [Abstract][Full Text] [Related]
20. Agonist actions of Bay K 8644, a dihydropyridine derivative, on the voltage-dependent calcium influx in smooth muscle cells of the rabbit mesenteric artery.
Kanmura Y; Itoh T; Kuriyama H
J Pharmacol Exp Ther; 1984 Dec; 231(3):717-23. PubMed ID: 6209390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
